Global Neuromuscular Blocking Drug Market Research Report 2021

1 Neuromuscular Blocking Drug Market Overview

• 1.1 Product Overview and Scope of Neuromuscular Blocking Drug
• 1.2 Neuromuscular Blocking Drug Segment by Type
  • 1.2.1 Global Neuromuscular Blocking Drug Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Non-polarizing Agents
  • 1.2.3 Depolarizing Agents
• 1.3 Neuromuscular Blocking Drug Segment by Application
  • 1.3.1 Neuromuscular Blocking Drug Sales Comparison by Application: (2021-2027)
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Retail Pharmacy
  • 1.3.4 Online Pharmacy
  • 1.3.5 Others
• 1.4 Global Neuromuscular Blocking Drug Market Size Estimates and Forecasts
  • 1.4.1 Global Neuromuscular Blocking Drug Revenue 2016-2027
  • 1.4.2 Global Neuromuscular Blocking Drug Sales 2016-2027
  • 1.4.3 Neuromuscular Blocking Drug Market Size by Region: 2016 Versus 2021 Versus 2027

2 Neuromuscular Blocking Drug Market Competition by Manufacturers

• 2.1 Global Neuromuscular Blocking Drug Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Neuromuscular Blocking Drug Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Neuromuscular Blocking Drug Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Neuromuscular Blocking Drug Manufacturing Sites, Area Served, Product Type
• 2.5 Neuromuscular Blocking Drug Market Competitive Situation and Trends
  • 2.5.1 Neuromuscular Blocking Drug Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Neuromuscular Blocking Drug Players Market Share by Revenue
  • 2.5.3 Global Neuromuscular Blocking Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Neuromuscular Blocking Drug Retrospective Market Scenario by Region

• 3.1 Global Neuromuscular Blocking Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Neuromuscular Blocking Drug Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Neuromuscular Blocking Drug Market Facts & Figures by Country
  • 3.3.1 North America Neuromuscular Blocking Drug Sales by Country
  • 3.3.2 North America Neuromuscular Blocking Drug Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Neuromuscular Blocking Drug Market Facts & Figures by Country
  • 3.4.1 Europe Neuromuscular Blocking Drug Sales by Country
  • 3.4.2 Europe Neuromuscular Blocking Drug Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Neuromuscular Blocking Drug Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Neuromuscular Blocking Drug Sales by Region
  • 3.5.2 Asia Pacific Neuromuscular Blocking Drug Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Neuromuscular Blocking Drug Market Facts & Figures by Country
  • 3.6.1 Latin America Neuromuscular Blocking Drug Sales by Country
  • 3.6.2 Latin America Neuromuscular Blocking Drug Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Neuromuscular Blocking Drug Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Neuromuscular Blocking Drug Sales by Country
  • 3.7.2 Middle East and Africa Neuromuscular Blocking Drug Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global Neuromuscular Blocking Drug Historic Market Analysis by Type

• 4.1 Global Neuromuscular Blocking Drug Sales Market Share by Type (2016-2021)
• 4.2 Global Neuromuscular Blocking Drug Revenue Market Share by Type (2016-2021)
• 4.3 Global Neuromuscular Blocking Drug Price by Type (2016-2021)

5 Global Neuromuscular Blocking Drug Historic Market Analysis by Application

• 5.1 Global Neuromuscular Blocking Drug Sales Market Share by Application (2016-2021)
• 5.2 Global Neuromuscular Blocking Drug Revenue Market Share by Application (2016-2021)
• 5.3 Global Neuromuscular Blocking Drug Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Hikma Pharmaceuticals
  • 6.1.1 Hikma Pharmaceuticals Corporation Information
  • 6.1.2 Hikma Pharmaceuticals Description and Business Overview
  • 6.1.3 Hikma Pharmaceuticals Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Hikma Pharmaceuticals Product Portfolio
  • 6.1.5 Hikma Pharmaceuticals Recent Developments/Updates
• 6.2 Merck
  • 6.2.1 Merck Corporation Information
  • 6.2.2 Merck Description and Business Overview
  • 6.2.3 Merck Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Merck Product Portfolio
  • 6.2.5 Merck Recent Developments/Updates
• 6.3 Novartis
  • 6.3.1 Novartis Corporation Information
  • 6.3.2 Novartis Description and Business Overview
  • 6.3.3 Novartis Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Novartis Product Portfolio
  • 6.3.5 Novartis Recent Developments/Updates
• 6.4 Bayer
  • 6.4.1 Bayer Corporation Information
  • 6.4.2 Bayer Description and Business Overview
  • 6.4.3 Bayer Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Bayer Product Portfolio
  • 6.4.5 Bayer Recent Developments/Updates
• 6.5 Pfizer
  • 6.5.1 Pfizer Corporation Information
  • 6.5.2 Pfizer Description and Business Overview
  • 6.5.3 Pfizer Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Pfizer Product Portfolio
  • 6.5.5 Pfizer Recent Developments/Updates
• 6.6 AbbVie
  • 6.6.1 AbbVie Corporation Information
  • 6.6.2 AbbVie Description and Business Overview
  • 6.6.3 AbbVie Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 AbbVie Product Portfolio
  • 6.6.5 AbbVie Recent Developments/Updates
• 6.7 GSK
  • 6.6.1 GSK Corporation Information
  • 6.6.2 GSK Description and Business Overview
  • 6.6.3 GSK Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 GSK Product Portfolio
  • 6.7.5 GSK Recent Developments/Updates

7 Neuromuscular Blocking Drug Manufacturing Cost Analysis

• 7.1 Neuromuscular Blocking Drug Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Neuromuscular Blocking Drug
• 7.4 Neuromuscular Blocking Drug Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Neuromuscular Blocking Drug Distributors List
• 8.3 Neuromuscular Blocking Drug Customers

9 Neuromuscular Blocking Drug Market Dynamics

• 9.1 Neuromuscular Blocking Drug Industry Trends
• 9.2 Neuromuscular Blocking Drug Growth Drivers
• 9.3 Neuromuscular Blocking Drug Market Challenges
• 9.4 Neuromuscular Blocking Drug Market Restraints

10 Global Market Forecast

• 10.1 Neuromuscular Blocking Drug Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Neuromuscular Blocking Drug by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Neuromuscular Blocking Drug by Type (2022-2027)
• 10.2 Neuromuscular Blocking Drug Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Neuromuscular Blocking Drug by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Neuromuscular Blocking Drug by Application (2022-2027)
• 10.3 Neuromuscular Blocking Drug Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Neuromuscular Blocking Drug by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Neuromuscular Blocking Drug by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List